AU729505C - Evolving cellular DNA uptake by recursive sequence recombination - Google Patents
Evolving cellular DNA uptake by recursive sequence recombinationInfo
- Publication number
- AU729505C AU729505C AU23377/97A AU2337797A AU729505C AU 729505 C AU729505 C AU 729505C AU 23377/97 A AU23377/97 A AU 23377/97A AU 2337797 A AU2337797 A AU 2337797A AU 729505 C AU729505 C AU 729505C
- Authority
- AU
- Australia
- Prior art keywords
- cells
- recombinant
- library
- cell
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn - After Issue
Links
- 230000006798 recombination Effects 0.000 title claims description 190
- 238000005215 recombination Methods 0.000 title claims description 190
- 108091092356 cellular DNA Proteins 0.000 title description 4
- 210000004027 cell Anatomy 0.000 claims description 442
- 108090000623 proteins and genes Proteins 0.000 claims description 261
- 108020004414 DNA Proteins 0.000 claims description 153
- 239000013598 vector Substances 0.000 claims description 153
- 241000700605 Viruses Species 0.000 claims description 125
- 238000012216 screening Methods 0.000 claims description 120
- 238000000034 method Methods 0.000 claims description 118
- 239000003550 marker Substances 0.000 claims description 87
- 238000012546 transfer Methods 0.000 claims description 81
- 238000000338 in vitro Methods 0.000 claims description 35
- 238000004520 electroporation Methods 0.000 claims description 31
- 108070000030 Viral receptors Proteins 0.000 claims description 30
- 239000012634 fragment Substances 0.000 claims description 29
- 101150069263 tra gene Proteins 0.000 claims description 29
- 108020004511 Recombinant DNA Proteins 0.000 claims description 28
- 230000003612 virological effect Effects 0.000 claims description 28
- 208000015181 infectious disease Diseases 0.000 claims description 27
- 208000036142 Viral infection Diseases 0.000 claims description 26
- 238000001890 transfection Methods 0.000 claims description 26
- 230000009385 viral infection Effects 0.000 claims description 26
- 238000001727 in vivo Methods 0.000 claims description 21
- 150000007523 nucleic acids Chemical class 0.000 claims description 19
- 108020003175 receptors Proteins 0.000 claims description 17
- 230000010076 replication Effects 0.000 claims description 17
- 230000002708 enhancing effect Effects 0.000 claims description 16
- 230000014509 gene expression Effects 0.000 claims description 16
- 241000894007 species Species 0.000 claims description 16
- 230000001902 propagating effect Effects 0.000 claims description 15
- 239000002773 nucleotide Substances 0.000 claims description 12
- 125000003729 nucleotide group Chemical group 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 11
- 108020004707 nucleic acids Proteins 0.000 claims description 11
- 241000588724 Escherichia coli Species 0.000 claims description 10
- 230000035772 mutation Effects 0.000 claims description 10
- 239000003471 mutagenic agent Substances 0.000 claims description 9
- 238000000137 annealing Methods 0.000 claims description 7
- 238000002744 homologous recombination Methods 0.000 claims description 7
- 230000006801 homologous recombination Effects 0.000 claims description 7
- 235000019687 Lamb Nutrition 0.000 claims description 6
- 108020005202 Viral DNA Proteins 0.000 claims description 5
- 108700005077 Viral Genes Proteins 0.000 claims description 4
- 238000012986 modification Methods 0.000 claims description 4
- 230000004048 modification Effects 0.000 claims description 4
- 231100000219 mutagenic Toxicity 0.000 claims description 4
- 230000003505 mutagenic effect Effects 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 230000002101 lytic effect Effects 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 2
- 239000000758 substrate Substances 0.000 description 92
- 239000013612 plasmid Substances 0.000 description 32
- 239000000047 product Substances 0.000 description 21
- 230000021615 conjugation Effects 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 13
- 230000006870 function Effects 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 12
- 239000007858 starting material Substances 0.000 description 11
- 230000001580 bacterial effect Effects 0.000 description 10
- 230000001413 cellular effect Effects 0.000 description 10
- 210000000349 chromosome Anatomy 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- 230000003321 amplification Effects 0.000 description 8
- 230000002759 chromosomal effect Effects 0.000 description 8
- 238000010367 cloning Methods 0.000 description 8
- 238000003199 nucleic acid amplification method Methods 0.000 description 8
- 239000013600 plasmid vector Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 230000000644 propagated effect Effects 0.000 description 7
- 239000013603 viral vector Substances 0.000 description 7
- 241000701959 Escherichia virus Lambda Species 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 108091033319 polynucleotide Proteins 0.000 description 6
- 102000040430 polynucleotide Human genes 0.000 description 6
- 239000002157 polynucleotide Substances 0.000 description 6
- 102000053602 DNA Human genes 0.000 description 5
- 241000724791 Filamentous phage Species 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 101100398653 Yersinia pestis lamB1 gene Proteins 0.000 description 4
- 230000003190 augmentative effect Effects 0.000 description 4
- 239000013611 chromosomal DNA Substances 0.000 description 4
- 238000010353 genetic engineering Methods 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 101150012518 lamB gene Proteins 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108091029865 Exogenous DNA Proteins 0.000 description 3
- 241000606790 Haemophilus Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000588653 Neisseria Species 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 102000011412 Complement 3d Receptors Human genes 0.000 description 2
- 108010023729 Complement 3d Receptors Proteins 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 101150003028 Hprt1 gene Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 241000712079 Measles morbillivirus Species 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 206010042566 Superinfection Diseases 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000004700 cellular uptake Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000001320 lysogenic effect Effects 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000004153 renaturation Methods 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 101150090434 sxy gene Proteins 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 229910052721 tungsten Inorganic materials 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- -1 3-galactosidase Proteins 0.000 description 1
- 241000589291 Acinetobacter Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000589155 Agrobacterium tumefaciens Species 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 241000219194 Arabidopsis Species 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 206010003594 Ataxia telangiectasia Diseases 0.000 description 1
- 102100036008 CD48 antigen Human genes 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 108091027551 Cointegrate Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 108010080611 Cytosine Deaminase Proteins 0.000 description 1
- 102000000311 Cytosine Deaminase Human genes 0.000 description 1
- 108010054814 DNA Gyrase Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000588698 Erwinia Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 241000219146 Gossypium Species 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 108010045198 H-2 Antigens Proteins 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 description 1
- 101000716130 Homo sapiens CD48 antigen Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 241000711467 Human coronavirus 229E Species 0.000 description 1
- 244000025221 Humulus lupulus Species 0.000 description 1
- 235000008694 Humulus lupulus Nutrition 0.000 description 1
- 108010042653 IgA receptor Proteins 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 102000002297 Laminin Receptors Human genes 0.000 description 1
- 108010000851 Laminin Receptors Proteins 0.000 description 1
- 241000255777 Lepidoptera Species 0.000 description 1
- 108700005090 Lethal Genes Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000221960 Neurospora Species 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 206010073261 Ovarian theca cell tumour Diseases 0.000 description 1
- 241000221945 Podospora Species 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 108010055016 Rec A Recombinases Proteins 0.000 description 1
- 102000001218 Rec A Recombinases Human genes 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 241000702263 Reovirus sp. Species 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 101710176276 SSB protein Proteins 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- 101710126859 Single-stranded DNA-binding protein Proteins 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 208000003028 Stuttering Diseases 0.000 description 1
- 241000192584 Synechocystis Species 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 101000865057 Thermococcus litoralis DNA polymerase Proteins 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 108091006374 cAMP receptor proteins Proteins 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 238000012219 cassette mutagenesis Methods 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 101150098857 comA gene Proteins 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 101150084863 cya gene Proteins 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000005059 dormancy Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000013412 genome amplification Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 101150002589 recF gene Proteins 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000032537 response to toxin Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 101150065190 term gene Proteins 0.000 description 1
- 208000001644 thecoma Diseases 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 208000005925 vesicular stomatitis Diseases 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
- C12N15/1027—Mutagenizing nucleic acids by DNA shuffling, e.g. RSR, STEP, RPR
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Cell Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Ecology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62143096A | 1996-03-25 | 1996-03-25 | |
| US08/621430 | 1996-03-25 | ||
| US08/792409 | 1997-02-03 | ||
| US08/792,409 US6096548A (en) | 1996-03-25 | 1997-02-03 | Method for directing evolution of a virus |
| PCT/US1997/004494 WO1997035957A1 (en) | 1996-03-25 | 1997-03-20 | Evolving cellular dna uptake by recursive sequence recombination |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU27671/02A Division AU2767102A (en) | 1996-03-25 | 2002-03-26 | Evolving cellular DNA uptake by recursive sequence recombination |
| AU27672/02A Division AU2767202A (en) | 1996-03-25 | 2002-03-26 | Eving cellular DNA uptake by recursive sequence recombination |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2337797A AU2337797A (en) | 1997-10-17 |
| AU729505B2 AU729505B2 (en) | 2001-02-01 |
| AU729505C true AU729505C (en) | 2006-02-23 |
Family
ID=27088953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU23377/97A Withdrawn - After Issue AU729505C (en) | 1996-03-25 | 1997-03-20 | Evolving cellular DNA uptake by recursive sequence recombination |
Country Status (6)
| Country | Link |
|---|---|
| US (5) | US6096548A (en:Method) |
| EP (1) | EP0932670A1 (en:Method) |
| JP (1) | JP2002514901A (en:Method) |
| AU (1) | AU729505C (en:Method) |
| IL (1) | IL126191A0 (en:Method) |
| WO (1) | WO1997035957A1 (en:Method) |
Families Citing this family (285)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060257890A1 (en) | 1996-05-20 | 2006-11-16 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US6995017B1 (en) | 1994-02-17 | 2006-02-07 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US6309883B1 (en) | 1994-02-17 | 2001-10-30 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US6335160B1 (en) | 1995-02-17 | 2002-01-01 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
| US6117679A (en) | 1994-02-17 | 2000-09-12 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US6165793A (en) * | 1996-03-25 | 2000-12-26 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US5837458A (en) * | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US6406855B1 (en) | 1994-02-17 | 2002-06-18 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
| US6395547B1 (en) | 1994-02-17 | 2002-05-28 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US5958672A (en) | 1995-07-18 | 1999-09-28 | Diversa Corporation | Protein activity screening of clones having DNA from uncultivated microorganisms |
| US6939689B2 (en) | 1995-12-07 | 2005-09-06 | Diversa Corporation | Exonuclease-mediated nucleic acid reassembly in directed evolution |
| US6740506B2 (en) | 1995-12-07 | 2004-05-25 | Diversa Corporation | End selection in directed evolution |
| US6764835B2 (en) | 1995-12-07 | 2004-07-20 | Diversa Corporation | Saturation mutageneis in directed evolution |
| US5830696A (en) | 1996-12-05 | 1998-11-03 | Diversa Corporation | Directed evolution of thermophilic enzymes |
| US5965408A (en) * | 1996-07-09 | 1999-10-12 | Diversa Corporation | Method of DNA reassembly by interrupting synthesis |
| US6358709B1 (en) | 1995-12-07 | 2002-03-19 | Diversa Corporation | End selection in directed evolution |
| US6713279B1 (en) | 1995-12-07 | 2004-03-30 | Diversa Corporation | Non-stochastic generation of genetic vaccines and enzymes |
| US6489145B1 (en) * | 1996-07-09 | 2002-12-03 | Diversa Corporation | Method of DNA shuffling |
| US7018793B1 (en) | 1995-12-07 | 2006-03-28 | Diversa Corporation | Combinatorial screening of mixed populations of organisms |
| US6537776B1 (en) | 1999-06-14 | 2003-03-25 | Diversa Corporation | Synthetic ligation reassembly in directed evolution |
| US6361974B1 (en) | 1995-12-07 | 2002-03-26 | Diversa Corporation | Exonuclease-mediated nucleic acid reassembly in directed evolution |
| US6506602B1 (en) | 1996-03-25 | 2003-01-14 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US6242211B1 (en) | 1996-04-24 | 2001-06-05 | Terragen Discovery, Inc. | Methods for generating and screening novel metabolic pathways |
| CA2266423A1 (en) * | 1996-09-27 | 1998-04-02 | Maxygen, Inc. | Methods for optimization of gene therapy by recursive sequence shuffling and selection |
| US20060002949A1 (en) | 1996-11-14 | 2006-01-05 | Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. | Transcutaneous immunization without heterologous adjuvant |
| US6797276B1 (en) | 1996-11-14 | 2004-09-28 | The United States Of America As Represented By The Secretary Of The Army | Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response |
| US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
| US20070009930A1 (en) * | 1996-12-18 | 2007-01-11 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
| US7148054B2 (en) | 1997-01-17 | 2006-12-12 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
| US6326204B1 (en) | 1997-01-17 | 2001-12-04 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
| ATE334225T1 (de) * | 1997-01-17 | 2006-08-15 | Maxygen Inc | Evolution prokaryotischer ganzer zellen durch rekursive sequenzrekombination |
| US6159688A (en) * | 1997-03-18 | 2000-12-12 | Novo Nordisk A/S | Methods of producing polynucleotide variants |
| US6159687A (en) * | 1997-03-18 | 2000-12-12 | Novo Nordisk A/S | Methods for generating recombined polynucleotides |
| WO1999021979A1 (en) | 1997-10-28 | 1999-05-06 | Maxygen, Inc. | Human papillomavirus vectors |
| US6596539B1 (en) * | 1997-10-31 | 2003-07-22 | Maxygen, Inc. | Modification of virus tropism and host range by viral genome shuffling |
| KR20010032861A (ko) | 1997-12-08 | 2001-04-25 | 캘리포니아 인스티튜트 오브 테크놀로지 | 폴리뉴클레오티드 및 폴리펩티드 서열을 형성하는 방법 |
| US6541011B2 (en) | 1998-02-11 | 2003-04-01 | Maxygen, Inc. | Antigen library immunization |
| JP2002503478A (ja) * | 1998-02-11 | 2002-02-05 | マキシジェン， インコーポレイテッド | 遺伝子ワクチンベクターの標的化 |
| EP1518927A3 (en) * | 1998-02-11 | 2005-06-22 | Maxygen, Inc. | Optimization of immunomodulatory properties of genetic vaccines |
| US7390619B1 (en) * | 1998-02-11 | 2008-06-24 | Maxygen, Inc. | Optimization of immunomodulatory properties of genetic vaccines |
| BR9910174A (pt) | 1998-05-01 | 2001-03-06 | Maxygen Inc | Processo para se obter um gene recombinante otimizado de resistência à praga, biblioteca, e, processo para se obter um organismo que seja patogênico a uma praga de vegetal |
| US6902918B1 (en) | 1998-05-21 | 2005-06-07 | California Institute Of Technology | Oxygenase enzymes and screening method |
| US7153655B2 (en) * | 1998-06-16 | 2006-12-26 | Alligator Bioscience Ab | Method for in vitro molecular evolution of protein function involving the use of exonuclease enzyme and two populations of parent polynucleotide sequence |
| AU4441699A (en) | 1998-06-17 | 2000-01-05 | Maxygen, Inc. | Method for producing polynucleotides with desired properties |
| US6365408B1 (en) | 1998-06-19 | 2002-04-02 | Maxygen, Inc. | Methods of evolving a polynucleotides by mutagenesis and recombination |
| US6951719B1 (en) * | 1999-08-11 | 2005-10-04 | Proteus S.A. | Process for obtaining recombined nucleotide sequences in vitro, libraries of sequences and sequences thus obtained |
| AU5347999A (en) | 1998-08-12 | 2000-03-06 | Maxygen, Inc. | Dna shuffling of monooxygenase genes for production of industrial chemicals |
| US20040191772A1 (en) * | 1998-08-12 | 2004-09-30 | Dupret Daniel Marc | Method of shuffling polynucleotides using templates |
| CA2345203A1 (en) | 1998-10-07 | 2000-04-13 | Maxygen Inc. | Dna shuffling to produce nucleic acids for mycotoxin detoxification |
| EP1129184A1 (en) | 1998-11-10 | 2001-09-05 | Maxygen, Inc. | Modified adp-glucose pyrophosphorylase for improvement and optimation of plant phenotypes |
| US6438561B1 (en) * | 1998-11-19 | 2002-08-20 | Navigation Technologies Corp. | Method and system for using real-time traffic broadcasts with navigation systems |
| US6376246B1 (en) | 1999-02-05 | 2002-04-23 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
| US20030054390A1 (en) * | 1999-01-19 | 2003-03-20 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
| US6917882B2 (en) * | 1999-01-19 | 2005-07-12 | Maxygen, Inc. | Methods for making character strings, polynucleotides and polypeptides having desired characteristics |
| US6436675B1 (en) | 1999-09-28 | 2002-08-20 | Maxygen, Inc. | Use of codon-varied oligonucleotide synthesis for synthetic shuffling |
| US6368861B1 (en) | 1999-01-19 | 2002-04-09 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
| EP1151409A1 (en) * | 1999-01-18 | 2001-11-07 | Maxygen, Inc. | Methods of populating data stuctures for use in evolutionary simulations |
| US6961664B2 (en) | 1999-01-19 | 2005-11-01 | Maxygen | Methods of populating data structures for use in evolutionary simulations |
| US7873477B1 (en) | 2001-08-21 | 2011-01-18 | Codexis Mayflower Holdings, Llc | Method and system using systematically varied data libraries |
| US20070065838A1 (en) * | 1999-01-19 | 2007-03-22 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
| ATE465459T1 (de) | 1999-01-19 | 2010-05-15 | Maxygen Inc | Durch oligonukleotide-vermittelte nukleinsäuren- rekombination |
| US8457903B1 (en) | 1999-01-19 | 2013-06-04 | Codexis Mayflower Holdings, Llc | Method and/or apparatus for determining codons |
| US7702464B1 (en) | 2001-08-21 | 2010-04-20 | Maxygen, Inc. | Method and apparatus for codon determining |
| US7024312B1 (en) * | 1999-01-19 | 2006-04-04 | Maxygen, Inc. | Methods for making character strings, polynucleotides and polypeptides having desired characteristics |
| US20090130718A1 (en) * | 1999-02-04 | 2009-05-21 | Diversa Corporation | Gene site saturation mutagenesis |
| US7384387B1 (en) | 1999-02-11 | 2008-06-10 | Maxygen, Inc. | High throughput mass spectrometry |
| JP3399518B2 (ja) * | 1999-03-03 | 2003-04-21 | インターナショナル・ビジネス・マシーンズ・コーポレーション | 半導体構造およびその製造方法 |
| US6531316B1 (en) | 1999-03-05 | 2003-03-11 | Maxyag, Inc. | Encryption of traits using split gene sequences and engineered genetic elements |
| CA2362737A1 (en) | 1999-03-05 | 2000-09-08 | Maxygen, Inc. | Recombination of insertion modified nucleic acids |
| AU5805500A (en) * | 1999-07-07 | 2001-01-30 | Maxygen Aps | A method for preparing modified polypeptides |
| ES2272299T3 (es) | 1999-08-12 | 2007-05-01 | Pfizer Products Inc. | Gen de streptomyces avermitilis que dirige la relacion de avermectinas b2:b1. |
| US20040002474A1 (en) * | 1999-10-07 | 2004-01-01 | Maxygen Inc. | IFN-alpha homologues |
| US7430477B2 (en) * | 1999-10-12 | 2008-09-30 | Maxygen, Inc. | Methods of populating data structures for use in evolutionary simulations |
| EP1230269A2 (en) | 1999-11-03 | 2002-08-14 | Maxygen, Inc. | Antibody diversity generation |
| US6686515B1 (en) | 1999-11-23 | 2004-02-03 | Maxygen, Inc. | Homologous recombination in plants |
| US7115712B1 (en) | 1999-12-02 | 2006-10-03 | Maxygen, Inc. | Cytokine polypeptides |
| AU2788101A (en) * | 2000-01-11 | 2001-07-24 | Maxygen, Inc. | Integrated systems and methods for diversity generation and screening |
| AU2001241939A1 (en) * | 2000-02-28 | 2001-09-12 | Maxygen, Inc. | Single-stranded nucleic acid template-mediated recombination and nucleic acid fragment isolation |
| EP1276861A2 (en) * | 2000-03-24 | 2003-01-22 | Maxygen, Inc. | Methods for modulating cellular and organismal phenotypes |
| US7115403B1 (en) | 2000-05-16 | 2006-10-03 | The California Institute Of Technology | Directed evolution of galactose oxidase enzymes |
| US6686188B2 (en) * | 2000-05-26 | 2004-02-03 | Amersham Plc | Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle |
| US6762031B2 (en) | 2000-06-16 | 2004-07-13 | University Of Medicine And Dentistry Of New Jersey | Targeting viral vectors to specific cells |
| US7074590B2 (en) * | 2000-06-23 | 2006-07-11 | Maxygen, Inc. | Chimeric promoters |
| AU2001272978A1 (en) * | 2000-06-23 | 2002-01-08 | Maxygen, Inc. | Novel co-stimulatory molecules |
| WO2002004629A2 (en) * | 2000-07-07 | 2002-01-17 | Maxygen, Inc. | Molecular breeding of transposable elements |
| US6858422B2 (en) * | 2000-07-13 | 2005-02-22 | Codexis, Inc. | Lipase genes |
| WO2002010183A1 (en) * | 2000-07-31 | 2002-02-07 | Menzel, Rolf | Compositions and methods for directed gene assembly |
| EP1317535A2 (en) * | 2000-08-24 | 2003-06-11 | Maxygen, Inc. | Constructs and their use in metabolic pathway engineering |
| US7045283B2 (en) | 2000-10-18 | 2006-05-16 | The Regents Of The University Of California | Methods of high-throughput screening for internalizing antibodies |
| WO2005012515A2 (en) | 2003-04-29 | 2005-02-10 | Pioneer Hi-Bred International, Inc. | Novel glyphosate-n-acetyltransferase (gat) genes |
| US6958213B2 (en) | 2000-12-12 | 2005-10-25 | Alligator Bioscience Ab | Method for in vitro molecular evolution of protein function |
| US20020086292A1 (en) | 2000-12-22 | 2002-07-04 | Shigeaki Harayama | Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules |
| ATE398461T1 (de) | 2001-02-13 | 2008-07-15 | Us Gov Sec Army | Impstoffe zur transkutanen immunisierung gegen reisediarrhö |
| US7465567B2 (en) | 2001-04-16 | 2008-12-16 | California Institute Of Technology | Peroxide-driven cytochrome P450 oxygenase variants |
| US7226768B2 (en) | 2001-07-20 | 2007-06-05 | The California Institute Of Technology | Cytochrome P450 oxygenases |
| US20040078837A1 (en) * | 2001-08-02 | 2004-04-22 | Shannon Mark E. | Four human zinc-finger-containing proteins: MDZ3, MDZ4, MDZ7 and MDZ12 |
| US7647184B2 (en) * | 2001-08-27 | 2010-01-12 | Hanall Pharmaceuticals, Co. Ltd | High throughput directed evolution by rational mutagenesis |
| EP2305313B1 (en) | 2001-10-10 | 2014-03-26 | ratiopharm GmbH | Remodelling and glycoconjugation of interferon-alpha (IFNa) |
| WO2003035842A2 (en) * | 2001-10-24 | 2003-05-01 | Dyax Corporation | Hybridization control of sequence variation |
| US6768476B2 (en) * | 2001-12-05 | 2004-07-27 | Etenna Corporation | Capacitively-loaded bent-wire monopole on an artificial magnetic conductor |
| US20040009498A1 (en) * | 2002-01-14 | 2004-01-15 | Diversa Corporation | Chimeric antigen binding molecules and methods for making and using them |
| US20040096826A1 (en) * | 2002-01-30 | 2004-05-20 | Evans Glen A. | Methods for creating recombination products between nucleotide sequences |
| AU2003230549A1 (en) * | 2002-01-31 | 2003-09-02 | Washington State University Research Foundation | Methods and vectors for facilitating site-specific recombination |
| US20030224404A1 (en) * | 2002-02-25 | 2003-12-04 | Manuel Vega | High throughput directed evolution of nucleic acids by rational mutagenesis |
| WO2003072054A2 (en) * | 2002-02-25 | 2003-09-04 | Cabot Corporation | Custom ligand design for biomolecular filtration and purification for bioseperation |
| AU2003267943C1 (en) | 2002-02-26 | 2009-05-21 | Altravax, Inc. | Novel flavivirus antigens |
| US7226771B2 (en) | 2002-04-19 | 2007-06-05 | Diversa Corporation | Phospholipases, nucleic acids encoding them and methods for making and using them |
| BRPI0309391B1 (pt) | 2002-04-19 | 2018-10-30 | Dsm Food Specialties B V | vetor compreendendo ácido nucléico que codifica polipeptídeo com atividade de fosfolipase, célula transformada, preparado de proteína, método de preparação e métodos relacionados |
| JP4372679B2 (ja) * | 2002-05-17 | 2009-11-25 | アリゲーター・バイオサイエンス・アーベー | タンパク質機能をインヴィトロで分子進化させる方法 |
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| AU2003304275A1 (en) | 2002-08-06 | 2005-01-21 | Pioneer Hi-Bred International, Inc. | Ap1 amine oxidase variants |
| US20060020396A1 (en) * | 2002-09-09 | 2006-01-26 | Rene Gantier | Rational directed protein evolution using two-dimensional rational mutagenesis scanning |
| US7611700B2 (en) | 2002-09-09 | 2009-11-03 | Hanall Pharmaceuticals, Co., Ltd. | Protease resistant modified interferon alpha polypeptides |
| US20050202438A1 (en) * | 2002-09-09 | 2005-09-15 | Rene Gantier | Rational directed protein evolution using two-dimensional rational mutagenesis scanning |
| US7563600B2 (en) | 2002-09-12 | 2009-07-21 | Combimatrix Corporation | Microarray synthesis and assembly of gene-length polynucleotides |
| EP2194133B1 (en) | 2003-03-06 | 2015-12-02 | BASF Enzymes LLC | Amylases, nucleic acids encoding them and methods for making and using them |
| EP2853593B1 (en) | 2003-03-07 | 2017-10-04 | DSM IP Assets B.V. | Hydrolases, nucleic acids encoding them and mehods for making and using them |
| DK1613733T3 (en) | 2003-04-04 | 2015-08-31 | Basf Enzymes Llc | PEKTATLYASER, nucleic acids encoding them, and methods for making and using the |
| EP2055189A1 (en) | 2003-04-09 | 2009-05-06 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
| WO2005017105A2 (en) | 2003-06-17 | 2005-02-24 | California University Of Technology | Regio- and enantioselective alkane hydroxylation with modified cytochrome p450 |
| US9233131B2 (en) | 2003-06-30 | 2016-01-12 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
| US9441244B2 (en) | 2003-06-30 | 2016-09-13 | The Regents Of The University Of California | Mutant adeno-associated virus virions and methods of use thereof |
| CN103484485B (zh) | 2003-07-02 | 2017-08-15 | Bp法人北美有限公司 | 葡聚糖酶，编码它们的核酸以及制备和使用它们的方法 |
| EP1668113B1 (en) | 2003-08-11 | 2013-06-19 | Verenium Corporation | Laccases, nucleic acids encoding them and methods for making and using them |
| US7435570B2 (en) | 2003-08-11 | 2008-10-14 | California Institute Of Technology | Thermostable peroxide-driven cytochrome P450 oxygenase variants and methods of use |
| DE602005023727D1 (de) | 2004-06-09 | 2010-11-04 | Pioneer Hi Bred Int | Plastiden transit peptide |
| EP1791853B1 (en) | 2004-06-16 | 2014-02-26 | DSM IP Assets B.V. | Compositions and methods for enzymatic decolorization of chlorophyll |
| DK1867207T3 (da) * | 2005-01-17 | 2008-10-13 | Widex As | Et apparat og en fremgangsmåde til drift af et höreapparat |
| US20090038023A1 (en) | 2005-03-10 | 2009-02-05 | Verenium Corporation | Lyase Enzymes, Nucleic Acids Encoding Them and Methods For Making and Using Them |
| BRPI0609140A2 (pt) | 2005-03-15 | 2010-02-17 | Verenium Corp | celulases, ácidos nucléicos que codificam eles e métodos para a produção e uso deles |
| US8715988B2 (en) | 2005-03-28 | 2014-05-06 | California Institute Of Technology | Alkane oxidation by modified hydroxylases |
| US11214817B2 (en) | 2005-03-28 | 2022-01-04 | California Institute Of Technology | Alkane oxidation by modified hydroxylases |
| CA2873914A1 (en) | 2005-06-21 | 2007-01-04 | Xoma (Us) Llc | Il-1.beta. binding antibodies and fragments thereof |
| WO2007005053A1 (en) * | 2005-06-30 | 2007-01-11 | Codon Devices, Inc. | Hierarchical assembly methods for genome engineering |
| GB2432366B (en) * | 2005-11-19 | 2007-11-21 | Alligator Bioscience Ab | A method for in vitro molecular evolution of protein function |
| EP1987142A4 (en) | 2006-02-02 | 2009-07-15 | Verenium Corp | ESTERASES AND ASSOCIATED NUCLEIC ACIDS AND METHODS |
| NZ595495A (en) | 2006-02-10 | 2013-05-31 | Verenium Corp | Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them |
| DK1989302T3 (en) | 2006-02-14 | 2018-07-23 | Bp Corp North America Inc | XYLANASES, NUCLEIC ACID CODING THEM AND PROCEDURES FOR THEIR PREPARATION AND USE |
| US7485446B2 (en) | 2006-02-21 | 2009-02-03 | The Board Of Trustees Of The University Of Illinois | Stable retrovirus and methods of use |
| EP2112227B1 (en) | 2006-03-07 | 2013-05-15 | Cargill, Incorporated | Aldolases, nucleic acids encoding them and methods for making and using them |
| MX2008011442A (es) | 2006-03-07 | 2008-11-18 | Verenium Corp | Aldolasas, acidos nucleicos que las codifican, y metodos para hacer y usar las mismas. |
| US8252559B2 (en) | 2006-08-04 | 2012-08-28 | The California Institute Of Technology | Methods and systems for selective fluorination of organic molecules |
| US8026085B2 (en) | 2006-08-04 | 2011-09-27 | California Institute Of Technology | Methods and systems for selective fluorination of organic molecules |
| CA3020590A1 (en) | 2006-08-04 | 2009-02-12 | Bp Corporation North America Inc. | Glucanases, nucleic acids encoding them and methods for making and using them |
| WO2008027558A2 (en) | 2006-08-31 | 2008-03-06 | Codon Devices, Inc. | Iterative nucleic acid assembly using activation of vector-encoded traits |
| EP2617728B1 (en) | 2006-09-21 | 2016-03-09 | BASF Enzymes LLC | Phytases, nucleic acids encoding them and methods for making and using them |
| ES2451266T3 (es) | 2006-09-21 | 2014-03-26 | Dsm Ip Assets B.V. | Fosfolipasas, ácidos nucleicos que las codifican, y métodos para obtenerlas y usarlas |
| MX2009006782A (es) | 2006-12-21 | 2009-09-21 | Verenium Corp | Amilasas y glucoamilasas, acidos nucleicos que las codifican y metodos para formarlas y usarlas. |
| JP2010516296A (ja) | 2007-01-30 | 2010-05-20 | ヴェレニウム コーポレイション | リグノセルロース性物質を処理する酵素、前記をコードする核酸並びに前記を製造及び使用する方法 |
| AU2008307371B2 (en) | 2007-10-03 | 2015-05-28 | Bp Corporation North America Inc. | Xylanases, nucleic acids encoding them and methods for making and using them |
| BRPI0822218A2 (pt) | 2008-01-03 | 2015-06-23 | Verenium Corp | Transferases e oxidorredutases, ácidos nucleicos que as codificam e métodos para fazê-las e usá-las. |
| US8541220B2 (en) | 2008-01-03 | 2013-09-24 | Verenium Corporation | Isomerases, nucleic acids encoding them and methods for making and using them |
| AU2009223632B2 (en) * | 2008-03-10 | 2014-03-06 | Gangagen, Inc. | Reducing conjugative plasmids in bacteria |
| WO2009143397A2 (en) | 2008-05-23 | 2009-11-26 | E. I. Du Pont De Nemours And Company | Novel dgat genes for increased seed storage lipid production and altered fatty acid profiles in oilseed plants |
| US8357503B2 (en) | 2008-08-29 | 2013-01-22 | Bunge Oils, Inc. | Hydrolases, nucleic acids encoding them and methods for making and using them |
| US8153391B2 (en) | 2008-08-29 | 2012-04-10 | Bunge Oils, Inc. | Hydrolases, nucleic acids encoding them and methods for making and using them |
| US8198062B2 (en) | 2008-08-29 | 2012-06-12 | Dsm Ip Assets B.V. | Hydrolases, nucleic acids encoding them and methods for making and using them |
| DK2346995T3 (en) | 2008-09-26 | 2019-02-11 | Tocagen Inc | GENETERIVE VECTORS AND CYTOSINDEAMINASES |
| BRPI1011160A8 (pt) | 2009-05-21 | 2018-01-02 | Verenium Corp | Fitases, preparação de proteína que as compreende, e seus usos |
| US8592649B2 (en) | 2009-08-20 | 2013-11-26 | Pioneer Hi Bred International Inc | Functional expression of shuffled yeast nitrate transporter (YNT1) in maize to improve nitrate uptake under low nitrate environment |
| UA109884C2 (uk) | 2009-10-16 | 2015-10-26 | Поліпептид, що має активність ферменту фосфатидилінозитол-специфічної фосфоліпази с, нуклеїнова кислота, що його кодує, та спосіб його виробництва і застосування | |
| UA111708C2 (uk) | 2009-10-16 | 2016-06-10 | Бандж Ойлз, Інк. | Спосіб рафінування олії |
| US10207240B2 (en) | 2009-11-03 | 2019-02-19 | Gen9, Inc. | Methods and microfluidic devices for the manipulation of droplets in high fidelity polynucleotide assembly |
| WO2011066185A1 (en) | 2009-11-25 | 2011-06-03 | Gen9, Inc. | Microfluidic devices and methods for gene synthesis |
| WO2011082304A1 (en) | 2009-12-31 | 2011-07-07 | Pioneer Hi-Bred International, Inc. | Engineering plant resistance to diseases caused by pathogens |
| US9217144B2 (en) | 2010-01-07 | 2015-12-22 | Gen9, Inc. | Assembly of high fidelity polynucleotides |
| WO2012021794A1 (en) | 2010-08-13 | 2012-02-16 | Pioneer Hi-Bred International, Inc. | Chimeric promoters and methods of use |
| WO2012024662A2 (en) | 2010-08-20 | 2012-02-23 | Codexis, Inc. | Expression constructs comprising fungal promoters |
| WO2012024698A1 (en) | 2010-08-20 | 2012-02-23 | Codexis, Inc. | Use of glycoside hydrolase 61 family proteins in processing of cellulose |
| US8663624B2 (en) | 2010-10-06 | 2014-03-04 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
| WO2012064975A1 (en) | 2010-11-12 | 2012-05-18 | Gen9, Inc. | Protein arrays and methods of using and making the same |
| CA3132011A1 (en) | 2010-11-12 | 2012-06-14 | Gen9, Inc. | Methods and devices for nucleic acids synthesis |
| EP2691517A4 (en) | 2011-03-30 | 2015-04-22 | Codexis Inc | FERMENTATION OF PENTOSES BY A RECOMBINANT MICROORGANISM |
| ES2994914T3 (en) | 2011-04-22 | 2025-02-04 | Univ California | Adeno-associated virus virions with variant capsid and methods of use thereof |
| US8778652B2 (en) | 2011-06-30 | 2014-07-15 | Codexis, Inc. | Pentose fermentation by a recombinant microorganism |
| US9322007B2 (en) | 2011-07-22 | 2016-04-26 | The California Institute Of Technology | Stable fungal Cel6 enzyme variants |
| BR112014004171A2 (pt) | 2011-08-22 | 2018-11-06 | Codexis Inc | variantes da proteína glicósideo hidrolase gh61 e cofatores que aumentam a atividade de gh61 |
| EP2944693B1 (en) | 2011-08-26 | 2019-04-24 | Gen9, Inc. | Compositions and methods for high fidelity assembly of nucleic acids |
| EP2760997A4 (en) | 2011-09-30 | 2015-02-11 | Codexis Inc | MUSHROOM PROTEASE |
| US9574010B2 (en) | 2011-11-04 | 2017-02-21 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| BR112014015030A2 (pt) | 2011-12-20 | 2017-06-13 | Codexis Inc | variantes da endoflucanase 1b (eg1b) |
| US9150853B2 (en) | 2012-03-21 | 2015-10-06 | Gen9, Inc. | Methods for screening proteins using DNA encoded chemical libraries as templates for enzyme catalysis |
| CA2871505C (en) | 2012-04-24 | 2021-10-12 | Gen9, Inc. | Methods for sorting nucleic acids and multiplexed preparative in vitro cloning |
| CN104411823A (zh) | 2012-05-04 | 2015-03-11 | 纳幕尔杜邦公司 | 包含具有大范围核酸酶活性的序列的组合物和方法 |
| WO2013188313A2 (en) | 2012-06-11 | 2013-12-19 | Codexis, Inc. | Fungal xylanases and xylosidases |
| EP2864531B2 (en) | 2012-06-25 | 2022-08-03 | Gen9, Inc. | Methods for nucleic acid assembly and high throughput sequencing |
| EP2922953A4 (en) | 2012-11-20 | 2016-11-09 | Shell Int Research | PENTOSEFERMENTATION BY A RECOMBINANT MICROORGANISM |
| CA2904537A1 (en) | 2013-03-14 | 2014-09-25 | Pioneer Hi-Bred International, Inc. | Compositions having dicamba decarboxylase activity and methods of use |
| CA2905595A1 (en) | 2013-03-14 | 2014-09-25 | Pioneer Hi-Bred International, Inc. | Compositions having dicamba decarboxylase activity and methods of use |
| CA2901316A1 (en) | 2013-03-15 | 2014-09-25 | Pioneer Hi-Bred International, Inc. | Phi-4 polypeptides and methods for their use |
| SI2986722T1 (sl) | 2013-04-18 | 2019-07-31 | Codexis, Inc. | Umetni polipeptidi fenilalanin amonija liaze |
| JP6600624B2 (ja) | 2013-05-31 | 2019-10-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | アデノ随伴ウイルス変異体及びその使用方法 |
| CN106232820A (zh) | 2013-08-16 | 2016-12-14 | 先锋国际良种公司 | 杀昆虫蛋白及其使用方法 |
| ES2937045T3 (es) | 2013-09-13 | 2023-03-23 | Pioneer Hi Bred Int | Proteínas insecticidas y métodos para su uso |
| AU2014324669B2 (en) | 2013-09-27 | 2020-06-04 | Codexis, Inc. | Automated screening of enzyme variants |
| EP3068793B1 (en) | 2013-11-13 | 2021-02-17 | Codexis, Inc. | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds |
| EP3102684B1 (en) | 2014-02-07 | 2020-05-06 | Pioneer Hi-Bred International, Inc. | Insecticidal proteins and methods for their use |
| MX2016010187A (es) | 2014-02-07 | 2017-07-11 | Pioneer Hi Bred Int | Proteinas insecticidas y metodos para su uso. |
| CN112626125A (zh) | 2014-03-17 | 2021-04-09 | 阿德夫拉姆生物技术股份有限公司 | 用于视锥细胞中增强的基因表达的组合物和方法 |
| US9587263B2 (en) | 2014-03-26 | 2017-03-07 | General Electric Company | Isothermal amplification under low salt condition |
| EP3145536B1 (en) | 2014-04-16 | 2021-10-27 | Codexis, Inc. | Engineered tyrosine ammonia lyase |
| WO2015168600A2 (en) * | 2014-05-02 | 2015-11-05 | Tufts University | Methods and apparatus for transformation of naturally competent cells |
| WO2016007623A1 (en) | 2014-07-09 | 2016-01-14 | Codexis, Inc. | Novel p450-bm3 variants with improved activity |
| US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
| CA2963558C (en) | 2014-10-16 | 2023-04-04 | Pioneer Hi-Bred International, Inc. | Insecticidal proteins and methods for their use |
| CA2968275C (en) | 2014-11-25 | 2023-09-12 | Codexis, Inc. | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds |
| DK3237621T5 (da) | 2014-12-22 | 2024-10-14 | Codexis Inc | Varianter af human alpha-galactosidase |
| CA3246568A1 (en) | 2015-01-15 | 2025-11-04 | Pioneer Hi-Bred International, Inc. | Insecticidal proteins and methods of use |
| EP3256577B1 (en) | 2015-02-10 | 2020-08-26 | Codexis, Inc. | Ketoreductase polypeptides for the synthesis of chiral compounds |
| EP3265178A4 (en) | 2015-03-02 | 2018-09-05 | Adverum Biotechnologies, Inc. | Compositions and methods for intravitreal delivery of polynucleotides to retinal cones |
| BR112017019419B1 (pt) | 2015-03-11 | 2022-10-11 | E. I. Du Pont De Nemours And Company | Construto de dna, método de obtenção de uma planta transgênica e método para controlar uma população de praga de verme da raiz do milho |
| AU2016235163B2 (en) | 2015-03-24 | 2022-03-24 | The Regents Of The University Of California | Adeno-associated virus variants and methods of use thereof |
| AU2016258091B2 (en) | 2015-05-07 | 2020-10-01 | Codexis, Inc. | Penicillin-G acylases |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| CA2985198A1 (en) | 2015-05-19 | 2016-11-24 | Pioneer Hi-Bred International, Inc. | Insecticidal proteins and methods for their use |
| CA2991195C (en) | 2015-07-07 | 2021-06-29 | Codexis, Inc. | Novel p450-bm3 variants with improved activity |
| CN109475096B (zh) | 2015-08-06 | 2022-08-23 | 先锋国际良种公司 | 植物来源的杀昆虫蛋白及其使用方法 |
| CA3002995A1 (en) | 2015-12-18 | 2017-06-22 | Pioneer Hi-Bred International, Inc. | Insecticidal proteins and methods for their use |
| EA201892293A1 (ru) | 2016-05-04 | 2019-04-30 | Пайонир Хай-Бред Интернэшнл, Инк. | Инсектицидные белки и способы их применения |
| MX389364B (es) | 2016-05-05 | 2025-03-19 | Codexis Inc | Penicilina g acilasas |
| US10184117B2 (en) | 2016-06-09 | 2019-01-22 | Codexis, Inc. | Biocatalysts and methods for hydroxylation of chemical compounds |
| MX2018015534A (es) | 2016-06-15 | 2019-03-14 | Codexis Inc | Beta-glucosidasas dise?adas y metodos de glucosilacion. |
| US11155829B2 (en) | 2016-07-01 | 2021-10-26 | Pioneer Hi-Bred International, Inc. | Insecticidal proteins from plants and methods for their use |
| EP3490531A4 (en) | 2016-07-29 | 2020-06-03 | The Regents of The University of California | ADENO ASSOCIATED VIRUS VIRIONS WITH VARIABLE CAPSIDE AND METHOD FOR USE THEREOF |
| JP7316662B2 (ja) | 2016-08-26 | 2023-07-28 | コデクシス， インコーポレイテッド | 操作されたイミンレダクターゼ、ならびにケトン化合物およびアミン化合物の還元的アミノ化のための方法 |
| US11192925B2 (en) | 2016-10-19 | 2021-12-07 | Adverum Biotechnologies, Inc. | Modified AAV capsids and uses thereof |
| MX387927B (es) | 2016-11-01 | 2025-03-19 | Pioneer Hi Bred Int | Proteinas insecticidas y metodos para su uso. |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| BR112019012339A2 (pt) | 2016-12-14 | 2019-11-26 | Pioneer Hi Bred Int | polipeptídeo inseticida recombinante, composição, construto de dna, célula hospedeira, planta transgênica, método para inibir o crescimento ou extermínio de uma praga de inseto ou população de praga, polipeptídeo ipd093 quimérico e proteína de fusão |
| EP3565893A4 (en) | 2017-01-05 | 2020-12-09 | Codexis, Inc. | PENICILLIN G ACYLASES |
| AU2018215335B2 (en) | 2017-02-03 | 2020-10-01 | Tate & Lyle Solutions Usa Llc | Engineered glycosyltransferases and steviol glycoside glucosylation methods |
| CA3052794A1 (en) | 2017-02-08 | 2018-08-16 | Pioneer Hi-Bred International, Inc. | Insecticidal combinations of plant derived insecticidal proteins and methods for their use |
| KR102573324B1 (ko) | 2017-02-13 | 2023-08-30 | 코덱시스, 인코포레이티드 | 조작된 페닐알라닌 암모니아 리아제 폴리펩티드 |
| IL270091B2 (en) | 2017-04-27 | 2025-08-01 | Codexis Inc | Ketoroductase polypeptides and polynucleotides |
| PL3635101T3 (pl) | 2017-05-08 | 2021-12-13 | Codexis, Inc. | Poddane inżynierii warianty ligazy |
| JP7122009B2 (ja) | 2017-06-14 | 2022-08-19 | コデクシス， インコーポレイテッド | 産業上の生体触媒作用のための操作されたトランスアミナーゼポリペプチド |
| CN111051506B (zh) | 2017-06-27 | 2023-11-24 | 科德克希思公司 | 青霉素g酰化酶 |
| AU2018292104B2 (en) | 2017-06-30 | 2025-03-27 | Codexis, Inc. | T7 RNA polymerase variants |
| KR102773542B1 (ko) | 2017-06-30 | 2025-02-25 | 코덱시스, 인코포레이티드 | T7 rna 폴리머라제 변이체 |
| BR112019019015A2 (pt) | 2017-06-30 | 2020-04-14 | Univ California | vírions de vírus adeno-associado com capsídeos variantes e seus métodos de uso |
| BR112020003571A2 (pt) | 2017-08-28 | 2020-08-25 | The Regents Of The University Of California | variantes capsidiais de vírus adenoassociado e métodos de uso das mesmas |
| WO2019094301A1 (en) | 2017-11-07 | 2019-05-16 | Codexis, Inc. | Transglutaminase variants |
| JP2021506252A (ja) | 2017-12-13 | 2021-02-22 | コデクシス， インコーポレイテッド | アミドカップリングのためのカルボキシエステラーゼポリペプチド |
| CN115850420A (zh) | 2018-03-14 | 2023-03-28 | 先锋国际良种公司 | 来自植物的杀昆虫蛋白及其使用方法 |
| CN111867377B (zh) | 2018-03-14 | 2023-05-23 | 先锋国际良种公司 | 来自植物的杀昆虫蛋白及其使用方法 |
| US10900055B2 (en) | 2018-06-12 | 2021-01-26 | Codexis, Inc. | Engineered tyrosine ammonia lyase |
| KR20210032417A (ko) | 2018-07-09 | 2021-03-24 | 코덱시스, 인코포레이티드 | 조작된 데옥시리보스-포스페이트 알돌라아제 |
| MX2021000323A (es) | 2018-07-09 | 2021-03-25 | Codexis Inc | Enzimas de variante de pantotenato quinasa modificadas geneticamente. |
| SG11202012111UA (en) | 2018-07-09 | 2021-01-28 | Codexis Inc | Engineered purine nucleoside phosphorylase variant enzymes |
| WO2020014046A1 (en) | 2018-07-09 | 2020-01-16 | Codexis, Inc. | Engineered phosphopentomutase variant enzymes |
| WO2020014049A1 (en) | 2018-07-09 | 2020-01-16 | Codexis, Inc. | Engineered galactose oxidase variant enzymes |
| JP2021531749A (ja) | 2018-07-12 | 2021-11-25 | コデクシス， インコーポレイテッド | 操作されたフェニルアラニンアンモニアリアーゼポリペプチド |
| BR112021001661A8 (pt) | 2018-07-30 | 2022-08-09 | Codexis Inc | Glicosiltransferase modificada, polinucleotídeo modificado, vetor, célula hospedeira, métodos para produzir pelo menos uma glicosiltransferase modificada, para produzir pelo menos uma variante de sacarose sintase, para glicosilação de um substrato, para produzir rebaudiosídeo m, rebaudiosídeo a e/ou rebaudiosídeo i e rebaudiosídeo d, composição, sacarose sintase modificada, pelo menos um rebaudiosídeo, rebaudiosídeo m, rebaudiosídeo a, rebaudiosídeo i, e, rebaudiosídeo d. |
| CN113316635A (zh) | 2018-10-29 | 2021-08-27 | 科德克希思公司 | 工程化dna聚合酶变体 |
| AU2019397401A1 (en) | 2018-12-14 | 2021-06-17 | Codexis, Inc. | Engineered tyrosine ammonia lyase |
| KR102898199B1 (ko) | 2018-12-20 | 2025-12-09 | 코덱시스, 인코포레이티드 | 인간 알파 갈락토시다제 변이체 |
| WO2020150125A1 (en) | 2019-01-15 | 2020-07-23 | Codexis, Inc. | Engineered transaminase polypeptides |
| US12215359B2 (en) | 2019-05-01 | 2025-02-04 | Codexis, Inc. | Engineered glucose dehydrogenases and methods for the reductive amination of ketone and amine compounds |
| WO2020223102A1 (en) | 2019-05-01 | 2020-11-05 | Codexis, Inc. | Engineered imine reductases and methods for the reductive amination of ketone and amine compounds |
| JP7678580B2 (ja) | 2019-07-02 | 2025-05-16 | コデクシス， インコーポレイテッド | 操作されたスクロースホスホリラーゼバリアント酵素 |
| BR112021024819A2 (pt) | 2019-07-02 | 2022-01-25 | Codexis Inc | Acetato quinase engenheirada, composição, sequência de polinucleotídeos, vetor de expressão, célula hospedeira, e, método de produção de uma acetato quinase engenheirada |
| MX2022002473A (es) | 2019-08-30 | 2022-08-02 | Codexis Inc | Variantes de lipasa modificadas geneticamente. |
| JP2022547523A (ja) | 2019-09-12 | 2022-11-14 | コデクシス， インコーポレイテッド | １０－アセチル－３，７－ジヒドロキシフェノキサジンに対するペルオキシダーゼ活性 |
| JP7720098B2 (ja) | 2019-11-26 | 2025-08-07 | コデクシス， インコーポレイテッド | 化合物のヒドロキシル化のための生体触媒および方法 |
| KR20220129547A (ko) | 2019-12-20 | 2022-09-23 | 코덱시스, 인코포레이티드 | 조작된 산성 알파-글루코시다제 변이체 |
| BR112022013503A2 (pt) | 2020-01-10 | 2022-09-13 | Univ California | Plataforma biossintética para a produção de ácido olivetólico e análogos de ácido olivetólico |
| MX2022009531A (es) | 2020-02-04 | 2022-09-09 | Codexis Inc | Leucina descarboxilasas modificadas geneticamente. |
| JP2023521772A (ja) | 2020-04-10 | 2023-05-25 | コデクシス， インコーポレイテッド | 操作されたトランスアミナーゼポリペプチド |
| EP4182466A2 (en) | 2020-07-14 | 2023-05-24 | Pioneer Hi-Bred International, Inc. | Insecticidal proteins and methods for their use |
| CN117098847A (zh) | 2020-08-28 | 2023-11-21 | 科德克希思公司 | 工程化蛋白酶变体 |
| EP4204552A4 (en) | 2020-08-28 | 2024-10-16 | Codexis, Inc. | Engineered amylase variants |
| EP4262804A4 (en) | 2020-12-18 | 2025-02-12 | Codexis, Inc. | Engineered uridine phosphorylase variant enzymes |
| CA3214972A1 (en) | 2021-04-02 | 2022-10-06 | Codexis, Inc. | Engineered adenylate kinase variant enzymes |
| US11913036B2 (en) | 2021-04-02 | 2024-02-27 | Codexis, Inc. | Engineered acetate kinase variant enzymes |
| WO2022212832A1 (en) | 2021-04-02 | 2022-10-06 | Codexis, Inc. | Engineered cyclic gmp-amp synthase (cgas) variant enzymes |
| US12473557B2 (en) | 2021-04-02 | 2025-11-18 | Codexis, Inc. | Engineered guanylate kinase variant enzymes |
| AU2022279241A1 (en) | 2021-05-21 | 2023-11-30 | Codexis, Inc. | Engineered methionine gamma lyase variants |
| JP2024539636A (ja) | 2021-10-15 | 2024-10-29 | コデクシス， インコーポレイテッド | 操作されたｄｎａポリメラーゼバリアント |
| WO2023077169A2 (en) | 2021-11-01 | 2023-05-04 | Codexis, Inc. | Engineered leucine decarboxylases |
| US20250332284A1 (en) * | 2022-02-25 | 2025-10-30 | Georgia Tech Research Corporation | Modified plant virus system for delivery of nucleic acids into mammalian cells |
| EP4573553A1 (en) | 2022-08-15 | 2025-06-25 | ABSCI Corporation | Quantitative affinity activity specific cell enrichment |
| WO2025144700A1 (en) | 2023-12-27 | 2025-07-03 | Absci Corporation | Nanobody library screening using bacterial surface display |
| WO2025235589A1 (en) | 2024-05-08 | 2025-11-13 | Codexis, Inc. | Dna polymerase variants |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4784952A (en) * | 1984-10-01 | 1988-11-15 | The Regents Of The University Of California | Conferred susceptibility to lambda phage in non-coliform procaryotic hosts |
| JP2584613B2 (ja) | 1985-03-30 | 1997-02-26 | バリベ、マール | 組換えｄｎａ技術によってｄｎａ、ｒｎａ、ペプタイド、ポリペプタイド、または蛋白質を取得するための方法 |
| US5866363A (en) | 1985-08-28 | 1999-02-02 | Pieczenik; George | Method and means for sorting and identifying biological information |
| US5824469A (en) | 1986-07-17 | 1998-10-20 | University Of Washington | Method for producing novel DNA sequences with biological activity |
| US5763192A (en) | 1986-11-20 | 1998-06-09 | Ixsys, Incorporated | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
| DD282028A5 (de) | 1989-02-16 | 1990-08-29 | Akad Wissenschaften Ddr | Verfahren zur herstellung einer thermostabilen, hybriden bacillus-beta-1,3-1,4-glukanase |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| CA2016841C (en) | 1989-05-16 | 1999-09-21 | William D. Huse | A method for producing polymers having a preselected activity |
| AU652539B2 (en) | 1989-05-16 | 1994-09-01 | Medical Research Council | Co-expression of heteromeric receptors |
| CA2089362C (en) | 1990-08-24 | 2000-11-21 | William D. Huse | Methods of synthesizing oligonucleotides with random codons |
| US5264563A (en) | 1990-08-24 | 1993-11-23 | Ixsys Inc. | Process for synthesizing oligonucleotides with random codons |
| US5871974A (en) | 1990-09-28 | 1999-02-16 | Ixsys Inc. | Surface expression libraries of heteromeric receptors |
| US5770434A (en) | 1990-09-28 | 1998-06-23 | Ixsys Incorporated | Soluble peptides having constrained, secondary conformation in solution and method of making same |
| IL99553A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing oligonucleotides linked to expression elements,a kit for the preparation of vectors useful for the expression of a diverse population of random peptides and methods utilizing the same |
| IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| IL100460A (en) | 1990-12-20 | 1997-06-10 | Ixsys | Method for optimization of binding proteins and nucleic acids encoding a binding protein produced thereby |
| US5348867A (en) | 1991-11-15 | 1994-09-20 | George Georgiou | Expression of proteins on bacterial surface |
| CA2137547A1 (en) * | 1992-06-11 | 1993-12-23 | Daniel Meruelo | Chimeric receptor polypeptides, human h13 proteins and uses thereof |
| AU4925293A (en) | 1992-09-16 | 1994-04-12 | Board Of Regents, The University Of Texas System | Mycoplasma pulmonis antigens and methods and compositions for use in cloning and vaccination |
| WO1994011496A1 (en) | 1992-11-10 | 1994-05-26 | Ixsys, Inc. | Soluble peptides having constrained, secondary conformation in solution and method of making same |
| US5593972A (en) | 1993-01-26 | 1997-01-14 | The Wistar Institute | Genetic immunization |
| US5837458A (en) * | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US6117679A (en) | 1994-02-17 | 2000-09-12 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US5834252A (en) * | 1995-04-18 | 1998-11-10 | Glaxo Group Limited | End-complementary polymerase reaction |
| US5928905A (en) | 1995-04-18 | 1999-07-27 | Glaxo Group Limited | End-complementary polymerase reaction |
| US6165793A (en) | 1996-03-25 | 2000-12-26 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US5783386A (en) | 1994-02-24 | 1998-07-21 | Agresearch, New Zealand Pastoral Agriculture Research Institute Ltd. | Mycobacteria virulence factors and a novel method for their identification |
| WO1995023846A1 (en) | 1994-03-04 | 1995-09-08 | University Of Medicine & Dentistry Of New Jersey | Cell-type specific gene transfer using retroviral vectors containing antibody-envelope and wild-type envelope-fusion proteins |
| US5516637A (en) * | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| GB9412844D0 (en) * | 1994-06-27 | 1994-08-17 | Medical Res Council | Improvements in or relating to therapeutic methods |
| US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
| WO1996029423A1 (en) | 1995-03-20 | 1996-09-26 | Baylor College Of Medicine | Compositions and methods for inducing infection by retroviral vectors outside of their host range |
| US5703057A (en) | 1995-04-07 | 1997-12-30 | Board Of Regents The University Of Texas System | Expression library immunization |
| US6004788A (en) | 1995-07-18 | 1999-12-21 | Diversa Corporation | Enzyme kits and libraries |
| US5958672A (en) * | 1995-07-18 | 1999-09-28 | Diversa Corporation | Protein activity screening of clones having DNA from uncultivated microorganisms |
| US6057103A (en) | 1995-07-18 | 2000-05-02 | Diversa Corporation | Screening for novel bioactivities |
| US6030779A (en) | 1995-07-18 | 2000-02-29 | Diversa Corporation | Screening for novel bioactivities |
| SE9503151D0 (sv) * | 1995-09-13 | 1995-09-13 | Bioinvent Internatioal Ab | Combined ligand and receptor display |
| US6171820B1 (en) | 1995-12-07 | 2001-01-09 | Diversa Corporation | Saturation mutagenesis in directed evolution |
| US5939250A (en) | 1995-12-07 | 1999-08-17 | Diversa Corporation | Production of enzymes having desired activities by mutagenesis |
| US5965408A (en) * | 1996-07-09 | 1999-10-12 | Diversa Corporation | Method of DNA reassembly by interrupting synthesis |
| WO2000077167A2 (en) | 1999-06-11 | 2000-12-21 | The General Hospital Corporation | Herpes simplex virus amplicon vector targeting system and method of using same |
-
1997
- 1997-02-03 US US08/792,409 patent/US6096548A/en not_active Expired - Lifetime
- 1997-03-20 JP JP53449797A patent/JP2002514901A/ja active Pending
- 1997-03-20 WO PCT/US1997/004494 patent/WO1997035957A1/en not_active Ceased
- 1997-03-20 EP EP97916119A patent/EP0932670A1/en not_active Withdrawn
- 1997-03-20 IL IL12619197A patent/IL126191A0/xx unknown
- 1997-03-20 AU AU23377/97A patent/AU729505C/en not_active Withdrawn - After Issue
-
1999
- 1999-11-01 US US09/430,931 patent/US6391552B2/en not_active Expired - Fee Related
- 1999-11-01 US US09/430,927 patent/US6358742B1/en not_active Expired - Lifetime
- 1999-11-01 US US09/431,003 patent/US6387702B1/en not_active Expired - Fee Related
-
2000
- 2000-11-28 US US09/724,067 patent/US6482647B1/en not_active Expired - Fee Related
Non-Patent Citations (2)
| Title |
|---|
| STEMMER,W.P.C. PROC. NATL. ACAD. SCI, USA VOL 91 (94) P10747 * |
| STENNER, W.P.C. NATURE VOL. 370 (1994) PP 389-391 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20020068363A1 (en) | 2002-06-06 |
| US6387702B1 (en) | 2002-05-14 |
| US6358742B1 (en) | 2002-03-19 |
| WO1997035957A1 (en) | 1997-10-02 |
| AU729505B2 (en) | 2001-02-01 |
| EP0932670A1 (en) | 1999-08-04 |
| JP2002514901A (ja) | 2002-05-21 |
| US6391552B2 (en) | 2002-05-21 |
| AU2337797A (en) | 1997-10-17 |
| IL126191A0 (en) | 1999-05-09 |
| US6482647B1 (en) | 2002-11-19 |
| US6096548A (en) | 2000-08-01 |
| EP0932670A4 (en:Method) | 1999-08-04 |
| US20010046707A1 (en) | 2001-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU729505C (en) | Evolving cellular DNA uptake by recursive sequence recombination | |
| WO1997035957A9 (en) | Evolving cellular dna uptake by recursive sequence recombination | |
| EP1007732B1 (en) | EVOLUTION OF procaryotic WHOLE CELLS BY RECURSIVE SEQUENCE RECOMBINATION | |
| Patten et al. | Applications of DNA shuffling to pharmaceuticals and vaccines | |
| EP1108058B1 (en) | Evolution of whole cells and organisms by recursive sequence recombination | |
| JP6552969B2 (ja) | 定方向進化のためのライブラリーの作製方法 | |
| CN111705365A (zh) | Crispr支持的多路基因组工程化 | |
| JP2016104033A (ja) | タンパク質および核酸の連続的指向性進化 | |
| JP7531914B2 (ja) | 改良されたハイスループットコンビナトリアル遺伝子改変システムおよび最適化されたＣａｓ９酵素変異体 | |
| CN116179513B (zh) | 一种Cpf1蛋白及其在基因编辑中的应用 | |
| US7820413B2 (en) | Incrementally truncated nucleic acids and methods of making same | |
| EP1504098A2 (en) | A method for in vitro molecular evolution of protein function | |
| CN113166741A (zh) | Dna文库的多重确定性组装 | |
| AU2767202A (en) | Eving cellular DNA uptake by recursive sequence recombination | |
| CA2247930A1 (en) | Evolving cellular dna uptake by recursive sequence recombination | |
| AU2767102A (en) | Evolving cellular DNA uptake by recursive sequence recombination | |
| WO2002061142A2 (en) | Methods for homology-driven reassembly of nucleic acid sequences | |
| US20070294785A1 (en) | Methods for generating genetic diversity by permutational mutagenesis | |
| US20100041033A1 (en) | Site specific system for generating diversity protein sequences | |
| EP1381680A1 (en) | Template-mediated, ligation-oriented method of nonrandomly shuffling polynucleotides | |
| AU2002338443A1 (en) | Template-mediated, ligation-oriented method of nonrandomly shuffling polynucleotides | |
| HK40057701A (en) | Multiplexed deterministic assembly of dna libraries | |
| AU2001286528A1 (en) | Methods and compositions for directed molecular evolution using DNA-end modification |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NBA | Allowances - extensions of time- section 223(1) |
Free format text: THE TIME IN WHICH TO EXTEND THE 21 MONTH DATE SO AS TO RECEIVE THE PRIORITY DOCUM ENT HAS BEEN EXTENDED TO 20010127 |
|
| CB | Opposition filed |
Opponent name: DIVERSA CORPORATION |